Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
18 Years and older, Male and Female
KO-TIP-007 (primary)
NCI-2018-02535
Summary
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study
evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort
will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with
HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study including
HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who
consent to provide first line outcome data and additional follow up.
Objectives
KO-TIP-007 is an international, multicenter, open-label, 2 cohort, non-comparative,
pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN) and the
impact of HRAS mutations on response to first line systemic therapies for HNSCC (SEQ-HN).
KO-TIP-007 has 2 study cohorts. The first study cohort, named AIM-HN, includes HNSCC
subjects with HRAS mutations. AIM-HN subjects will receive treatment with tipifarnib and
the outcome of this cohort will be evaluated for ORR by an independent review facility.
The second study cohort, SEQ-HN, is an observational sub-study including HNSCC patients
in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to
provide first line outcome data and additional follow up.
HNSCC patients in whom HRAS mutations are identified and who meet eligibility criteria
will be offered participation in AIM-HN. HNSCC patients in whom HRAS mutations are not
identified may participate in SEQ-HN only. These patients will be followed and the
comparison of outcomes of HRAS mutant and HRAS wild type HNSCC will address the
exploratory objective to determine the effect of HRAS mutation on the ORR of first line
systemic therapy in patients with recurrent/metastatic HNSCC. Outcome data from
subsequent lines of therapy will be collected.
Eligibility
- Inclusion Criteria:
AIM-HN
1. At least 18 years of age.
2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx,
sinonasal, nasopharyngeal, or unknown primary) of squamous histology not amenable to
local therapy with curative intent (surgery or radiation therapy with or without
chemotherapy).
3. Documented treatment failure from most recent prior therapy (e.g. tumor progression,
clinical deterioration, or recurrence), and from at least one prior
platinum-containing regimen, in any treatment setting.
4. Known tumor missense HRAS mutation.
5. Measurable disease by RECIST v1.1.
6. ECOG performance status of 0-1.
7. Acceptable liver, renal and hematological function
8. Other protocol defined inclusion criteria may apply.
Exclusion Criteria:
1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or
nonsquamous histologies (e.g. mucosal melanoma).
2. Received treatment for unstable angina within prior year, myocardial infarction
within the prior year, cerebro-vascular attack within the prior year, history of New
York Heart Association grade III or greater congestive heart failure, or current
serious cardiac arrhythmia requiring medication except atrial fibrillation.
3. Non-tolerable Grade 2 or = Grade 3 neuropathy or evidence of unstable neurological
symptoms within 4 weeks of Cycle 1 Day 1.
4. Active, uncontrolled bacterial, viral or fungal infections requiring systemic
therapy. Known history of infection with human immunodeficiency virus or an active
infection with hepatitis B or hepatitis C.
5. Received treatment for non-cancer related liver disease within prior year.
6. Other protocol defined exclusion criteria may apply
Inclusion Criteria: SEQ-HN
1. At least 18 years of age.
2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx,
sinonasal, nasopharyngeal, or unknown primary) of squamous histology.
3. Will or has received at least one systemic anti-cancer therapy for recurrent or
metastatic HNSCC.
4. HRAS wildtype (i.e., have no identified tumor missense HRAS mutation).
5. Other protocol defined inclusion criteria may apply
Exclusion Criteria: SEQ-HN
1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or
nonsquamous histologies (e.g. mucosal melanoma).
5. Other protocol defined exclusion criteria may apply
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.